JP7275130B2 - Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態 - Google Patents

Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態 Download PDF

Info

Publication number
JP7275130B2
JP7275130B2 JP2020528129A JP2020528129A JP7275130B2 JP 7275130 B2 JP7275130 B2 JP 7275130B2 JP 2020528129 A JP2020528129 A JP 2020528129A JP 2020528129 A JP2020528129 A JP 2020528129A JP 7275130 B2 JP7275130 B2 JP 7275130B2
Authority
JP
Japan
Prior art keywords
crystalline
compound
crystalline form
certain embodiments
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020528129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504338A (ja
JP2021504338A5 (https=
Inventor
ジェイコブ ピー． サイズモア，
リーティン グオ，
マハムード ミルメフラビ，
イェチン スー，
シィジェイ チャン，
エリック シモン，
ジェフリー ディー． ウイルソン，
リサーラガ， ホセ ルイス リオス
Original Assignee
アジオス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64734113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7275130(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アジオス ファーマシューティカルズ， インコーポレイテッド filed Critical アジオス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2021504338A publication Critical patent/JP2021504338A/ja
Publication of JP2021504338A5 publication Critical patent/JP2021504338A5/ja
Priority to JP2023076364A priority Critical patent/JP2023093762A/ja
Application granted granted Critical
Publication of JP7275130B2 publication Critical patent/JP7275130B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020528129A 2017-11-22 2018-11-21 Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態 Active JP7275130B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023076364A JP2023093762A (ja) 2017-11-22 2023-05-02 Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762589822P 2017-11-22 2017-11-22
US62/589,822 2017-11-22
US201862691709P 2018-06-29 2018-06-29
US62/691,709 2018-06-29
PCT/US2018/062197 WO2019104134A1 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076364A Division JP2023093762A (ja) 2017-11-22 2023-05-02 Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態

Publications (3)

Publication Number Publication Date
JP2021504338A JP2021504338A (ja) 2021-02-15
JP2021504338A5 JP2021504338A5 (https=) 2023-01-30
JP7275130B2 true JP7275130B2 (ja) 2023-05-17

Family

ID=64734113

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020528129A Active JP7275130B2 (ja) 2017-11-22 2018-11-21 Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態
JP2023076364A Withdrawn JP2023093762A (ja) 2017-11-22 2023-05-02 Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023076364A Withdrawn JP2023093762A (ja) 2017-11-22 2023-05-02 Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態

Country Status (27)

Country Link
US (2) US11254652B2 (https=)
EP (2) EP3713919B1 (https=)
JP (2) JP7275130B2 (https=)
KR (3) KR102777452B1 (https=)
CN (2) CN117551030A (https=)
AU (2) AU2018373122B2 (https=)
BR (1) BR112020010185A2 (https=)
CA (1) CA3081945A1 (https=)
DK (1) DK3713919T3 (https=)
ES (1) ES2959764T3 (https=)
FI (1) FI3713919T3 (https=)
HR (1) HRP20230931T1 (https=)
HU (1) HUE063264T2 (https=)
IL (3) IL274488B2 (https=)
LT (1) LT3713919T (https=)
MD (1) MD3713919T2 (https=)
MX (2) MX2020005348A (https=)
PH (1) PH12020550644A1 (https=)
PL (1) PL3713919T3 (https=)
PT (1) PT3713919T (https=)
RS (1) RS64592B1 (https=)
SG (1) SG11202004587XA (https=)
SI (1) SI3713919T1 (https=)
SM (1) SMT202300327T1 (https=)
TW (1) TWI808108B (https=)
UA (1) UA127502C2 (https=)
WO (1) WO2019104134A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI598337B (zh) * 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
LT3483164T (lt) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
KR102777452B1 (ko) 2017-11-22 2025-03-10 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020237047A1 (en) * 2019-05-22 2020-11-26 Agios Pharmaceuticals, Inc. Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
US11878049B1 (en) 2019-06-14 2024-01-23 Agios Pharmaceuticals, Inc. Mitapivat therapy and modulators of cytochrome P450
HRP20251148T1 (hr) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag Pripravci koji aktiviraju piruvat-kinazu r (pkr)
WO2021154987A1 (en) 2020-01-28 2021-08-05 Teva Pharmaceuticals International Gmbh Solid state forms of mitapivat and process for preparation thereof
CN116568281A (zh) * 2020-09-25 2023-08-08 安吉奥斯医药品有限公司 药物制剂
EP4216956A1 (en) * 2020-09-25 2023-08-02 Agios Pharmaceuticals, Inc. Pharmaceutical formulation
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023154036A1 (en) 2022-02-08 2023-08-17 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat
WO2022231627A1 (en) 2021-04-30 2022-11-03 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat for use in treating thalassemia
EP4329758A1 (en) * 2021-04-30 2024-03-06 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat
EP4147700A1 (en) * 2021-09-08 2023-03-15 LQT Therapeutics Inc. N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease
IL312679A (en) 2021-11-16 2024-07-01 Agios Pharmaceuticals Inc Compounds for the treatment of anemia associated with MDS and other conditions
WO2024084501A1 (en) 2022-10-17 2024-04-25 Mylan Laboratories Limited Crystalline polymorphs of mitapivat and mitapivat hemisulfate
ES2975743A1 (es) * 2022-11-22 2024-07-12 Moehs Iberica Sl Metodo de preparacion de mitapivat, intermedios de sintesis de mitapivat y metodos de preparacion de los mismos
WO2024228131A1 (en) * 2023-05-02 2024-11-07 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of 8-quinoline sulfonamide, n-[4-[[4(cyclopropylmethyl)-1-piperazinyl] carbonyl] phenyl]-sulfate and its process for preparation thereof
WO2025008787A1 (en) * 2023-07-05 2025-01-09 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of mitapivat hemisulfate
WO2025083627A1 (en) * 2023-10-18 2025-04-24 Apitoria Pharma Private Limited Novel crystalline forms of mitapivat sulfate and processes for preparation
WO2025146636A1 (en) * 2024-01-03 2025-07-10 Tianish Laboratories Private Limited Novel crystalline polymorphs of mitapivat sulfate salt

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506329A (ja) 1999-07-30 2003-02-18 ランバクシー ラボラトリーズ リミテッド セフポドキシメプロキセチルの改良アモルファス形態
JP2005521636A (ja) 2001-10-18 2005-07-21 シプラ・リミテッド 薬剤的に許容されるアモルファス形態のアレンドロ酸塩
JP2015528516A (ja) 2012-09-18 2015-09-28 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
WO2016201227A1 (en) 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU722662B2 (en) 1996-05-20 2000-08-10 Darwin Discovery Limited Quinoline sulfonamides as TNF inhibitors and as PDE-IV inhibitors
US20010041706A1 (en) 2000-03-24 2001-11-15 Synold Timothy W. Blockade of taxane metabolism
US20020055495A1 (en) 2000-09-05 2002-05-09 Anthony Jannetta Two-component anti-emetic composition
CN101711164B (zh) 2007-01-18 2014-06-04 密苏里-哥伦比亚大学 可修复肌纤维膜中的神经元型一氧化氮合酶的合成小/微-抗肌萎缩蛋白基因
TWI598337B (zh) * 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
AU2011283008A1 (en) 2010-07-30 2013-01-24 Merck Sharp & Dohme Corp. Inhibition of CYP3A drug metabolism
SMT202400081T1 (it) 2011-05-03 2024-03-13 Agios Pharmaceuticals Inc Attivatori della piruvato chinasi per uso in terapia
WO2013056153A1 (en) * 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
US9921221B2 (en) 2012-07-26 2018-03-20 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
AU2015225496A1 (en) 2014-03-03 2016-10-13 Sujata ACHARJEE Chimeric dystrophin-VSV-G-protein to treat dystrophinopathies
KR102777452B1 (ko) 2017-11-22 2025-03-10 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태
US11878049B1 (en) 2019-06-14 2024-01-23 Agios Pharmaceuticals, Inc. Mitapivat therapy and modulators of cytochrome P450

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506329A (ja) 1999-07-30 2003-02-18 ランバクシー ラボラトリーズ リミテッド セフポドキシメプロキセチルの改良アモルファス形態
JP2005521636A (ja) 2001-10-18 2005-07-21 シプラ・リミテッド 薬剤的に許容されるアモルファス形態のアレンドロ酸塩
JP2015528516A (ja) 2012-09-18 2015-09-28 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
WO2016201227A1 (en) 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
平山令明，有機化合物結晶作製ハンドブック，2008年，pp. 17-23,37-40,45-51,57-65
長瀬博監訳，最新 創薬化学 下巻，株式会社テクノミック，1999年09月25日，pp. 347-365
高田則幸，創薬段階における原薬Formスクリーニングと選択，PHARM STAGE，Vol. 6, No. 10，2007年01月15日，pp. 20-25

Also Published As

Publication number Publication date
IL322576A (en) 2025-10-01
IL274488A (en) 2020-06-30
US11254652B2 (en) 2022-02-22
KR20200090787A (ko) 2020-07-29
TW201930289A (zh) 2019-08-01
CN117551030A (zh) 2024-02-13
EP3713919B1 (en) 2023-08-02
IL305343B1 (en) 2025-09-01
AU2018373122B2 (en) 2023-11-09
HRP20230931T1 (hr) 2023-11-24
US12612381B2 (en) 2026-04-28
EP3713919A1 (en) 2020-09-30
SI3713919T1 (sl) 2023-10-30
UA127502C2 (uk) 2023-09-13
IL274488B2 (en) 2024-01-01
KR102682430B1 (ko) 2024-07-08
IL305343A (en) 2023-10-01
MX2020005348A (es) 2020-08-13
FI3713919T3 (fi) 2023-09-29
EP4285904A2 (en) 2023-12-06
MD3713919T2 (ro) 2024-02-29
LT3713919T (lt) 2023-10-10
MX2022009998A (es) 2022-09-19
AU2024200724A1 (en) 2024-02-22
TW202334115A (zh) 2023-09-01
PH12020550644A1 (en) 2021-04-26
CN111372920A (zh) 2020-07-03
CA3081945A1 (en) 2019-05-31
PT3713919T (pt) 2023-10-26
IL274488B1 (en) 2023-09-01
KR20250034202A (ko) 2025-03-10
ES2959764T3 (es) 2024-02-28
US20220220093A1 (en) 2022-07-14
HUE063264T2 (hu) 2024-01-28
WO2019104134A1 (en) 2019-05-31
EP4285904A3 (en) 2023-12-20
IL305343B2 (en) 2026-01-01
JP2021504338A (ja) 2021-02-15
BR112020010185A2 (pt) 2021-01-12
AU2018373122A1 (en) 2020-05-21
AU2024200724B2 (en) 2026-02-05
DK3713919T3 (da) 2023-09-25
PL3713919T3 (pl) 2023-12-27
CN111372920B (zh) 2023-10-20
SG11202004587XA (en) 2020-06-29
SMT202300327T1 (it) 2023-11-13
US20200277279A1 (en) 2020-09-03
RS64592B1 (sr) 2023-10-31
TWI808108B (zh) 2023-07-11
KR102777452B1 (ko) 2025-03-10
JP2023093762A (ja) 2023-07-04
KR20240108581A (ko) 2024-07-09

Similar Documents

Publication Publication Date Title
JP7275130B2 (ja) Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態
CN114026071B (zh) N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式
HK40104405A (en) Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
TWI922809B (zh) N-(4-(4-(環丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺醯胺之結晶型
EA042666B1 (ru) Кристаллические формы n-(4-(4-(циклопропилметил)пиперазин-1-карбонил)фенил)хинолин-8-сульфонамида
JP2025186242A (ja) ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211025

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230502

R150 Certificate of patent or registration of utility model

Ref document number: 7275130

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150